Edited on October 30, 2026
RSV and HMPV belong to the same viral family but are distinct respiratory pathogens. Similar symptoms do not imply the same diagnosis or identical preventive measures: The available RSV preventive measures should not be interpreted as protection against all Pneumoviridae. [1][3][9]
As Herbert Eder, I will explain why frequency therapy must also take these differences into account. In cases of acute illness, breathing, the ability to drink, and overall condition take precedence over a blanket classification based on viral family. [6][7]
RSV and HMPV are related but remain distinct
The Pneumoviridae were classified as a separate family from the Paramyxoviridae in 2016. RSV belongs to the genus Orthopneumovirus, and HMPV to the genus Metapneumovirus. The family also includes viruses from other animal species. However, their shared taxonomic classification does not imply that each of these viruses is a human pathogen. RSV remains a common and useful term in everyday clinical practice. [1]
A previous RSV infection does not provide lasting protection
According to the RKI, nearly all children have already been exposed to RSV by the end of their second year of life. This does not result in reliable, lifelong immunity. Recurrent infections can occur at any age. The notion that children are generally protected starting on their third birthday is therefore incorrect. A previous positive test result does not rule out a later RSV infection. [2]
Many reinfections are mild. However, the risk of severe illness is higher in certain groups, including very young children, premature infants, older adults, and people with underlying heart, lung, or immune system conditions. The RKI explicitly describes these differences. Neither age alone nor a previous uncomplicated infection guarantees that a current illness will follow the same course. [2]
HMPV is an important respiratory pathogen in its own right
HMPV can cause coughing, fever, a stuffy nose, and shortness of breath. It can affect both the upper and lower respiratory tracts. The CDC identifies young children, older adults, and people with weakened immune systems as particularly high-risk groups. The symptoms may resemble those of RSV, influenza, or other infections. Therefore, the causative pathogen cannot be reliably identified based on the sound of a cough. [3]
HMPV was first described in 2001 in a study of sick children. The researchers at the time also found serological evidence that the virus had been circulating among humans for decades. Discovery and first occurrence are therefore two different things. If HMPV appears more frequently in reports or laboratory findings today, this does not automatically mean that a completely new virus has emerged. [4]
Transmission and the infectious period aren't a stopwatch
RSV is transmitted, among other ways, through close contact, respiratory secretions containing the virus, and contaminated hands or objects. The CDC notes that the virus is often contagious even before the first symptoms appear and usually remains so for several days. In infants or immunocompromised individuals, viral shedding may persist for longer. Therefore, specific time estimates for how long the virus survives on individual surfaces do not provide a reliable protection plan for every everyday situation. [5]
In practice, what matters is following a simple, easy-to-implement routine: wash your hands before caring for a baby, keep frequently touched items clean, and postpone visits if you have respiratory symptoms. The NHS guidance specifically recommends keeping newborns away from people with cold symptoms. A smoke-free environment is also important. These individual measures complement one another; a quick, cursory glance at a visitor’s health is not a substitute for them. [6]
Monitor an infant's breathing and feeding
Bronchiolitis affects the small airways and may be accompanied by rapid or labored breathing, difficulty drinking, and abnormal breathing sounds. The NHS lists pauses in breathing, bluish or gray discoloration, and a limp child who is difficult to wake as signs of a medical emergency. If these symptoms occur, immediate medical attention is required. Do not wait for a high fever or a positive viral test result to develop. [6]
For the examination, please note approximately how much your child is drinking, how often their diapers are wet, and any changes in their breathing. A brief observation of the progression is helpful, but it should not delay any necessary evaluation. If you’re unsure, describe the specific change rather than just asking about a possible viral diagnosis.
Adults, too, can develop illnesses that require treatment
RSV often causes cold-like symptoms in adults, but it can worsen existing respiratory conditions. The CDC specifically mentions possible worsening of COPD or asthma. Shortness of breath, inadequate fluid intake, or worsening symptoms should be evaluated by a healthcare provider. A positive RSV test result does not automatically explain every instance of worsening symptoms and does not rule out an additional cause that requires treatment. [14]
If you have a known underlying medical condition, it’s helpful to have a plan in place that’s been discussed in advance. What changes should be reported? Which prescribed medications should be continued, and how? And who can be reached outside of office hours? Be sure to bring your current list of medications with you to your appointment. A winter illness is not a good reason to change important long-term medications without consulting your doctor.
When a Test Is Recommended
The RKI describes PCR methods for the direct detection of RSV, sometimes in conjunction with other respiratory pathogens. Rapid antigen tests are available, but they do not detect every infection with the same degree of reliability. Their accuracy depends, among other factors, on age, the stage of the illness, and the test used. Antibody testing plays a significantly smaller role in making immediate decisions. A negative rapid test result alone is therefore no substitute for medical evaluation if there are clear warning signs. [2]
HMPV can also be detected using molecular methods. The CDC emphasizes that testing can be helpful, for example, in cases of more severe illness or when making decisions regarding patient placement and further diagnostic testing. However, not every uncomplicated respiratory infection requires comprehensive viral screening. The key factor is whether the result changes a specific care decision. In severe cases, necessary treatment must not be delayed while waiting for laboratory results. [3]
Bronchiolitis is not routinely treated with asthma medications
The NICE guideline does not recommend routine antibiotics, salbutamol, or corticosteroids for typical bronchiolitis in infants and young children. Depending on the severity, however, support for oxygenation or fluid intake may be necessary. A wheezing sound is therefore not a sufficient reason to use an asthma inhaler, even if one is available. Other diagnoses or comorbidities may require different treatment decisions. [7]
When your child is discharged, ask for an explanation of what changes would require a follow-up visit. The guidelines emphasize the importance of providing this information to parents and caregivers. Also ask when the next follow-up visit is scheduled. A clear plan is especially helpful if symptoms worsen at night or if multiple people are taking turns caring for your child. [7]
Provide Support at Home; Ensure Safety While Sleeping
If medically appropriate home care is available, smaller, more frequent meals can make it easier for the child to drink. The NHS advises monitoring the child regularly and seeking help again if their condition worsens. A more upright position may be comfortable while the child is awake. However, this does not mean that a baby should be propped up on pillows to sleep or that a mattress should be tilted at an angle. [6]
The NHS pediatric information guide *Healthier Together* also recommends a flat sleeping surface for bronchiolitis and warns against raising the head or adding extra padding on your own. If you’re unsure, ask for a safe solution. Do not try to treat abnormal breathing simply by changing the child’s position. In cases of genuine respiratory distress, a medical evaluation is more important than searching for a supposedly beneficial sleeping position. [8]
Preventive antibodies are not a treatment for an acute infection
Nirsevimab, approved under the brand name Beyfortus, is a monoclonal antibody used to prevent certain RSV-related illnesses in infants and selected at-risk toddlers. The EMA describes its mechanism of action as specific binding to an RSV surface protein. This form of passive immunization involves the administration of ready-made antibodies. This is distinct from active vaccination, in which the body itself mounts an immune response. [9]
The randomized HARMONIE study enrolled more than 8,000 infants. Eleven children in the nirsevimab group and sixty in the standard-of-care group were hospitalized due to RSV-related lower respiratory tract disease. The results demonstrate a significant reduction in risk under the study conditions. They do not imply complete protection for every child, nor do they imply protection against all other respiratory viruses. [10]
Vaccines and other antibody products have their own areas of application
RSV vaccines are available for adults. The EMA also lists passive protection for the child through vaccination of the mother during pregnancy as a benefit of Abrysvo. Approval, individual recommendations, and coverage are separate issues. Discuss the appropriate course of action based on age, pre-existing conditions, stage of pregnancy, and your country’s current recommendations. [11]
Since April 2026, Clesrovimab has also been approved in the EU under the name Enflonsia for the prevention of lower respiratory tract RSV infections during the first RSV season. This, too, is an antibody preparation. Approval does not automatically mean that every product is available everywhere or is part of the same public program. The specific selection is made in accordance with the applicable recommendations. [13]
Check out the Austrian offerings for the season
The Austrian vaccination portal describes a free program for the 2026/27 season to provide passive immunization to infants during their first RSV season and to certain children who remain at risk during their second season. For adults, the RSV vaccine is generally recommended starting at age 60; for those at increased risk, it may be advisable to receive it earlier. Specific eligibility and scheduling should be determined based on the current program guidelines. [12]
The state of research is different for HMPV
According to CDC information, there is currently no approved vaccine for HMPV and no established specific antiviral treatment. Treatment focuses on supporting the affected functions. RSV vaccines and RSV antibodies should therefore not be viewed as general protection against the entire Pneumoviridae family. This clear distinction helps establish realistic expectations regarding prevention and treatment. [3]
Keep your medical reports and immunization records together. At your next appointment, ask which pathogen was detected and what purpose each measure serves. In the case of an acute illness, the focus is on breathing, fluid intake, and overall condition. You can then take your time planning for the next season to determine which proven preventive measure best suits your personal or family situation.
RSV, HMPV, and Frequency Therapy: Distinguishing Between Prevention and Acute Care
Nirsevimab was studied for the prevention of RSV-related illnesses. The demonstrated reduction in hospitalizations refers specifically to this particular intervention and not to any respiratory infection or the treatment of pre-existing conditions. [9][10]
The sources presented here do not provide clinical evidence of the efficacy of pneumovirus frequency programs. In cases of bronchiolitis, treatment is based on oxygen and fluid requirements; furthermore, the condition is not routinely treated in the same way as asthma. A device cannot replace the necessary clinical assessment. [7]
Related in-depth study in the subject area of frequency therapy and health education: RSV and the Classification of Frequency Therapy · Evaluating Frequency Therapy in Infants and Children.
Sources and Further Information
- ICTV: Family Pneumoviridae, Current Family Report. Retrieved October 29, 2026.
- RKI Guide: RSV Infections. Retrieved October 29, 2026.
- CDC: About Human Metapneumovirus, February 2026. Retrieved October 29, 2026.
- Van den Hoogen et al. 2001: First description of the human metapneumovirus. Retrieved October 29, 2026.
- CDC: How RSV Spreads. Retrieved October 29, 2026.
- NHS: Bronchiolitis, Patient Information, February 2026. Retrieved October 29, 2026.
- NICE NG9: Bronchiolitis in Children: Diagnosis and Management. Retrieved October 29, 2026.
- NHS Healthier Together: Bronchiolitis and RSV, Safe Home Care. Retrieved October 29, 2026.
- EMA: Beyfortus, Nirsevimab for RSV Prevention. Retrieved October 29, 2026.
- Drysdale et al. 2023: HARMONIE, a randomized trial of nirsevimab and hospitalizations. Retrieved October 29, 2026.
- EMA: Abrysvo, Approved Indications. Retrieved October 29, 2026.
- Austrian Vaccination Portal: RSV, 2026–27 Season. Retrieved October 29, 2026.
- EMA: Enflonsia, Clesrovimab, EU Approval in April 2026. Retrieved October 29, 2026.
- CDC: Symptoms and Care for RSV. Retrieved October 29, 2026.
Topic Overview: Pathogen Knowledge.
Comments are closed, but trackbacks and pingbacks are open.